DZ Bank AG Reiterates “Neutral” Rating for Qiagen N.V. (QGEN)
Qiagen N.V. (NASDAQ:QGEN)‘s stock had its “neutral” rating reissued by equities researchers at DZ Bank AG in a report released on Monday.
A number of other research analysts have also commented on the stock. Commerzbank Ag restated a “buy” rating on shares of Qiagen N.V. in a research note on Thursday, August 17th. Cowen and Company restated a “hold” rating and issued a $33.00 price objective on shares of Qiagen N.V. in a research note on Monday, August 14th. BidaskClub lowered shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Zacks Investment Research lowered shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, Independent Research GmbH upgraded shares of Qiagen N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $33.17.
Qiagen N.V. (QGEN) opened at 31.63 on Monday. Qiagen N.V. has a 1-year low of $24.86 and a 1-year high of $35.26. The stock has a 50 day moving average price of $32.76 and a 200-day moving average price of $31.36. The stock has a market capitalization of $7.22 billion, a P/E ratio of 96.73 and a beta of 1.14.
Qiagen N.V. (NASDAQ:QGEN) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The firm had revenue of $349 million for the quarter, compared to analyst estimates of $353.09 million. During the same period last year, the business earned $0.24 EPS. Qiagen N.V.’s revenue for the quarter was up 4.4% compared to the same quarter last year. Equities research analysts expect that Qiagen N.V. will post $1.22 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/30/dz-bank-ag-reiterates-neutral-rating-for-qiagen-n-v-qgen.html.
Several hedge funds have recently modified their holdings of QGEN. BlackRock Inc. increased its stake in shares of Qiagen N.V. by 8,793.4% in the first quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock valued at $227,114,000 after buying an additional 7,751,485 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Qiagen N.V. by 2,651.3% in the first quarter. Legal & General Group Plc now owns 1,896,813 shares of the company’s stock valued at $16,690,000 after buying an additional 1,827,871 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Qiagen N.V. during the first quarter valued at $46,480,000. Neuberger Berman Group LLC purchased a new stake in shares of Qiagen N.V. during the first quarter valued at $31,875,000. Finally, Renaissance Technologies LLC increased its stake in shares of Qiagen N.V. by 182.9% in the first quarter. Renaissance Technologies LLC now owns 1,514,898 shares of the company’s stock valued at $43,890,000 after buying an additional 979,498 shares during the last quarter. 63.01% of the stock is currently owned by institutional investors and hedge funds.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Stock Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related stocks with our FREE daily email newsletter.